Beacon Biosignals announced that it has acquired Cleveland Medical Devices Inc. (known as CleveMed), a leader in home sleep testing (HST) technology and services, in a strategic transaction that will strengthen both companies’ capabilities.
Jacob Donoghue, MD, PhD, CEO and co-founder of Beacon Biosignals, commented, “There is a lot we can learn from each other to expand and enhance our service offerings, including bringing the power of Beacon Biosignals’ AI-driven algorithms to CleveMed’s existing devices and offerings.”
Hani Kayyali, CEO and president of CleveMed, said, “We are so excited about this opportunity. With our fast-growing market presence and Beacon’s exceptional AI capabilities, this strategic partnership is uniquely positioned to expand access to quality care while addressing future sleep testing needs”.
Source: CleveMed
